Fernanda Rocha Chaves Moreira1, Tiago Almeida de Oliveira1, Nádia Eliza Ramos1, Maria Augusta Duarte Abreu1, Ana Cristina Simões E Silva2,3. 1. Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Avenida Alfredo Balena, 190, 2nd floor, room #281, Belo Horizonte, MG, 30130-100, Brazil. 2. Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Avenida Alfredo Balena, 190, 2nd floor, room #281, Belo Horizonte, MG, 30130-100, Brazil. acssilva@hotmail.com. 3. Department of Pediatrics, Faculty of Medicine, UFMG, Belo Horizonte, Brazil. acssilva@hotmail.com.
Abstract
BACKGROUND: In rheumatoid arthritis (RA) and osteoarthritis (OA), chronic inflammatory processes lead to progresive joint destruction. The renin-angiotensin system (RAS) is involved in the pathogenesis of RA and OA. The aim of this mini-review article is to summarize evidence on the role of RAS in RA and OA. METHODS: A non-systematic search in Pubmed included terms as "rheumatoid arthritis", "renin angiotensin system", "osteopenia", "RANKL", "DKK-1", "MMP", "inflammation", "angiogenesis", "local renin-angiotensin system", "angiotensin converting enzyme", "AT2 receptor", "Ang-(1-7)", "VEGF", "angiotensine receptor blocker", "angiotensin converting enzyme inhibitors", "renin inhibitors". RESULTS: Both RAS axes, the classical one, formed by angiotensin converting enzyme (ACE), angiotensin (Ang) II and AT1 receptor (AT1R) and the counter-regulatory one, composed by ACE2, Ang-(1-7) and the Mas receptor, modulate inflammation and tissue damage. Ang II activates pro-inflammatory mediators and oxidative stress. Conversely, Ang-(1-7) exerts anti-inflammatory actions, decreasing cytokine release, leukocyte attraction, density of vessels, tissue damage and fibrosis. Angiogenesis facilitates inflammatory cells invasion, while osteopenia causes joint dysfunction. Up-regulated osteoclastogenisis and down-regulated osteoblastogeneses were associaed with the activation of the classical RAS axis. Three different pathways, RANKL, DKK-1 and MMPs are enhanced by classical RAS activation. The treatment of RA included methotrexate and corticosteroids, which can cause side effects. Studies with angiotensin receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEi) and renin inhibitors have been conducted in experimental and clinical RA with promising results. CONCLUSION: The classical RAS activation is an important mechanism in RA pathogenesis and the benefit of ARB and ACEi administration should be further investigated.
BACKGROUND: In rheumatoid arthritis (RA) and osteoarthritis (OA), chronic inflammatory processes lead to progresive joint destruction. The renin-angiotensin system (RAS) is involved in the pathogenesis of RA and OA. The aim of this mini-review article is to summarize evidence on the role of RAS in RA and OA. METHODS: A non-systematic search in Pubmed included terms as "rheumatoid arthritis", "renin angiotensin system", "osteopenia", "RANKL", "DKK-1", "MMP", "inflammation", "angiogenesis", "local renin-angiotensin system", "angiotensin converting enzyme", "AT2 receptor", "Ang-(1-7)", "VEGF", "angiotensine receptor blocker", "angiotensin converting enzyme inhibitors", "renin inhibitors". RESULTS: Both RAS axes, the classical one, formed by angiotensin converting enzyme (ACE), angiotensin (Ang) II and AT1 receptor (AT1R) and the counter-regulatory one, composed by ACE2, Ang-(1-7) and the Mas receptor, modulate inflammation and tissue damage. Ang II activates pro-inflammatory mediators and oxidative stress. Conversely, Ang-(1-7) exerts anti-inflammatory actions, decreasing cytokine release, leukocyte attraction, density of vessels, tissue damage and fibrosis. Angiogenesis facilitates inflammatory cells invasion, while osteopenia causes joint dysfunction. Up-regulated osteoclastogenisis and down-regulated osteoblastogeneses were associaed with the activation of the classical RAS axis. Three different pathways, RANKL, DKK-1 and MMPs are enhanced by classical RAS activation. The treatment of RA included methotrexate and corticosteroids, which can cause side effects. Studies with angiotensin receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEi) and renin inhibitors have been conducted in experimental and clinical RA with promising results. CONCLUSION: The classical RAS activation is an important mechanism in RA pathogenesis and the benefit of ARB and ACEi administration should be further investigated.
Authors: Veli Cobankara; Mehmet Akif Oztürk; Sedat Kiraz; Ihsan Ertenli; Ibrahim C Haznedaroglu; Salih Pay; Meral Calgüneri Journal: Rheumatol Int Date: 2005-03-11 Impact factor: 2.631
Authors: Kátia D Silveira; Fernanda M Coelho; Angélica T Vieira; Lívia C Barroso; Celso M Queiroz-Junior; Vívian V Costa; Larissa F C Sousa; Marilene L Oliveira; Michael Bader; Tarcíla A Silva; Robson A S Santos; Ana Cristina Simões E Silva; Mauro M Teixeira Journal: Peptides Date: 2013-05-31 Impact factor: 3.750
Authors: Manuel J del Rey; Elena Izquierdo; Sergio Caja; Alicia Usategui; Begoña Santiago; María Galindo; José L Pablos Journal: Arthritis Rheum Date: 2009-10
Authors: Sven Wassmann; Michaela Stumpf; Kerstin Strehlow; Andreas Schmid; Bernhard Schieffer; Michael Böhm; Georg Nickenig Journal: Circ Res Date: 2003-12-29 Impact factor: 17.367
Authors: Faith Matcham; Ian C Scott; Lauren Rayner; Matthew Hotopf; Gabrielle H Kingsley; Sam Norton; David L Scott; Sophia Steer Journal: Semin Arthritis Rheum Date: 2014-05-29 Impact factor: 5.532
Authors: Panagiota Anyfanti; Athanasia Dara; Elena Angeloudi; Eleni Bekiari; Theodoros Dimitroulas; George D Kitas Journal: J Inflamm Res Date: 2021-12-14